Skip to main content
[Preprint]. 2023 Sep 12:rs.3.rs-3287211. [Version 1] doi: 10.21203/rs.3.rs-3287211/v1

Figure 3. Combined ATL-DC vaccine and TLR agonist treatment show trends of improved tumor control and patient survival.

Figure 3.

A, B, C, Progression-free survival (PFS, top) and overall survival (OS, bottom) of all patients (A), patient subset with GBM (B), or grade III glioma (C) in indicated treatment groups. P values, log-rank test.

D, E, Multivariate Cox proportional hazards analysis assessing the hazard ratios of tumor progression in TLR agonist treatment groups against placebo in all patients (D) or GBM subset after adjusting for other clinical covariates (Tx_Group=treatment group, RecurNum=number of recurrences prior to ATL-DC treatment).

F, MR-computed volumes of post-treatment, recurrent tumors in indicated treatment groups. P values, unpaired, two-sided Wilcoxon rank sum test.